This is a guidance document and not an organizational guideline. As such, it did not go
through the formal process required for guidelines. In addition, the radiopharmaceuticals …

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor
radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine …

Neuroendocrine tumours are a heterogeneous group of tumours arising from a variety of
specific chemical signalling cells in a range of organs. Superimposed on this intrinsic …

Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …

One should always be cautious of undertaking a rigorous examination of a subject lest
hubris interferes with balance and the confidence of “experience” undermines the rigor of …

The development of peptide receptor radionuclide therapy (PRRT) in disseminated
neuroendocrine tumors (NETs) has been a long and protracted process. The idea was born …

59 VOL. 57 NO. 1 MARCH 2019 SAJS in clinical practice. Decades of use have allowed a
clear identification of a patient sub-population in which dosimetry is essential for therapy …

Neuroendocrine tumours (NETs) constitute a heterogeneous group of neoplasms: they
include epithelial neuroendocrine carcinomas originating in multiple sites throughout the …

Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important
modality in the therapeutic armamentarium of advanced, metastatic or inoperable …

Peptide receptor radionuclide therapy (PRRT) has been a well-accepted and effective
therapeutic modality for inoperable or metastatic gastroenteropancreatic, bronchopulmonary …